Wall Street Journal: Lunesta off to strong start

Share this article:
Sepracor's Lunesta is exceeding early projections, selling briskly and eroding Ambien's market share in the sleeping pill category, according to an article appearing in today's Wall Street Journal.
Analysts told the Journal that Lunesta is off to one of the fastest prescription starts on record.
J.P. Morgan Chase analyst Corey Davis told the newspaper, that in the seven days through May 9, Lunesta had 42,508 new prescriptions, giving it a 9.8 percent share of new insomnia-drug prescriptions. In the same period, Sanofi-Aventis' Ambien registered 250,461 new prescriptions, or a 61 percent share, down from nearly 70 percent prior to Lunesta's launch, the article said.
Lunesta entered the market on April 4 and between then and May 9 totaled about 150,000 prescriptions – exceeding tallies of other widely used drugs in the same number of days after their launches, including Lipitor and Cialis.
Gregg Gilbert, an analyst at Merrill Lynch said in the Journal report that Lunesta's prescription sales figures, and a strong appetite for the drug, caused him to raise his sales estimates yesterday. Gilbert said he expected Lunesta will account for 18 percent of total sleep-drug prescriptions by 2009, up from a prior estimate of 15 .5 percent.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.